Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major pollen allergy markets are expected to exhibit a CAGR of 2.79% during 2024-2034.
The pollen allergy market has been comprehensively analyzed in IMARC's new report titled "Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pollen allergy, also known as allergic rhinitis or hay fever, refers to a common allergic reaction that occurs when a person's immune system overreacts to pollen from various plants, such as trees, grasses, and weeds. This triggers the production of histamine and other chemicals, leading to allergy symptoms. The severity of indications can vary from mild to serious, depending on the amount of pollen exposure. Individuals suffering from this ailment may experience sneezing, nasal congestion, runny nose, itchy or watery eyes, coughing, itching of the throat or ears, fatigue, headache, a reduced sense of taste or smell, etc. These symptoms can substantially affect a person's quality of life, interfering with sleep, work, and daily activities. The diagnosis of pollen allergy is typically based on a combination of the patient's clinical features, medical history, and physical examination. A blood workup is further recommended to measure the level of specific IgE antibodies produced in response to allergens. Additionally, the healthcare provider may also perform skin prick tests to determine the cause of underlying indications among patients.
The increasing cases of genetic predisposition, in which malfunctioning genes that influence barrier integrity are passed down from parents to their children, are primarily driving the pollen allergy market. In addition to this, the rising prevalence of autoimmune disorders and chronic illnesses, resulting in overactive or underactive immune responses among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antihistamines, such as cetirizine, fexofenadine, loratadine, etc., since they provide symptom relief by blocking the effects of histamine, a chemical released during an allergic reaction, is further bolstering the market growth. Apart from this, the inflating application of nasal corticosteroids to decrease inflammation in the nasal passages and promote quality of life is acting as another significant growth-inducing factor. Additionally, the emerging popularity of sublingual immunotherapy for the treatment of the disease on account of its numerous advantages, like high convenience, improved adherence, and a favorable safety profile over traditional allergy shots, is expected to drive the pollen allergy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pollen allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pollen allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pollen allergy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pollen allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pollen allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pollen allergy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pollen allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pollen allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pollen allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pollen allergy across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pollen allergy across the seven major markets?
What is the size of the pollen allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pollen allergy?
What will be the growth rate of patients across the seven major markets?
Pollen Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pollen allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pollen allergy market?
What are the key regulatory events related to the pollen allergy market?
What is the structure of clinical trial landscape by status related to the pollen allergy market?
What is the structure of clinical trial landscape by phase related to the pollen allergy market?
What is the structure of clinical trial landscape by route of administration related to the pollen allergy market?
The pollen allergy market has been comprehensively analyzed in IMARC's new report titled "Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pollen allergy, also known as allergic rhinitis or hay fever, refers to a common allergic reaction that occurs when a person's immune system overreacts to pollen from various plants, such as trees, grasses, and weeds. This triggers the production of histamine and other chemicals, leading to allergy symptoms. The severity of indications can vary from mild to serious, depending on the amount of pollen exposure. Individuals suffering from this ailment may experience sneezing, nasal congestion, runny nose, itchy or watery eyes, coughing, itching of the throat or ears, fatigue, headache, a reduced sense of taste or smell, etc. These symptoms can substantially affect a person's quality of life, interfering with sleep, work, and daily activities. The diagnosis of pollen allergy is typically based on a combination of the patient's clinical features, medical history, and physical examination. A blood workup is further recommended to measure the level of specific IgE antibodies produced in response to allergens. Additionally, the healthcare provider may also perform skin prick tests to determine the cause of underlying indications among patients.
The increasing cases of genetic predisposition, in which malfunctioning genes that influence barrier integrity are passed down from parents to their children, are primarily driving the pollen allergy market. In addition to this, the rising prevalence of autoimmune disorders and chronic illnesses, resulting in overactive or underactive immune responses among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antihistamines, such as cetirizine, fexofenadine, loratadine, etc., since they provide symptom relief by blocking the effects of histamine, a chemical released during an allergic reaction, is further bolstering the market growth. Apart from this, the inflating application of nasal corticosteroids to decrease inflammation in the nasal passages and promote quality of life is acting as another significant growth-inducing factor. Additionally, the emerging popularity of sublingual immunotherapy for the treatment of the disease on account of its numerous advantages, like high convenience, improved adherence, and a favorable safety profile over traditional allergy shots, is expected to drive the pollen allergy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the pollen allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pollen allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pollen allergy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pollen allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pollen allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pollen allergy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pollen allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pollen allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pollen allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pollen allergy across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pollen allergy across the seven major markets?
What is the size of the pollen allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pollen allergy?
What will be the growth rate of patients across the seven major markets?
Pollen Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pollen allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pollen allergy market?
What are the key regulatory events related to the pollen allergy market?
What is the structure of clinical trial landscape by status related to the pollen allergy market?
What is the structure of clinical trial landscape by phase related to the pollen allergy market?
What is the structure of clinical trial landscape by route of administration related to the pollen allergy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLLEN ALLERGY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLLEN ALLERGY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLLEN ALLERGY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLLEN ALLERGY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLLEN ALLERGY - UNMET NEEDS
10 POLLEN ALLERGY - KEY ENDPOINTS OF TREATMENT
11 POLLEN ALLERGY - MARKETED PRODUCTS
11.1 List of Pollen Allergy Marketed Drugs Across the Top 7 Markets
11.1.1 Grastek (Grass pollen allergy vaccine table) - ALK-Abello
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ragwitek (Ragweed allergy vaccine sublingual tablet) - ALK-Abello
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Oralair (Grass pollen allergy immunotherapy) - Stallergenes Greer plc
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLLEN ALLERGY - PIPELINE DRUGS
12.1 List of Pollen Allergy Pipeline Drugs Across the Top 7 Markets
12.1.1 REGN5713-5714-5715 - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLLEN ALLERGY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLLEN ALLERGY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLLEN ALLERGY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pollen Allergy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pollen Allergy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pollen Allergy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pollen Allergy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pollen Allergy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pollen Allergy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pollen Allergy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pollen Allergy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pollen Allergy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pollen Allergy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pollen Allergy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pollen Allergy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pollen Allergy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pollen Allergy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pollen Allergy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pollen Allergy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pollen Allergy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pollen Allergy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pollen Allergy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pollen Allergy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pollen Allergy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pollen Allergy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pollen Allergy - Access and Reimbursement Overview
16 POLLEN ALLERGY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLLEN ALLERGY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLLEN ALLERGY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLLEN ALLERGY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLLEN ALLERGY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLLEN ALLERGY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLLEN ALLERGY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLLEN ALLERGY - UNMET NEEDS
10 POLLEN ALLERGY - KEY ENDPOINTS OF TREATMENT
11 POLLEN ALLERGY - MARKETED PRODUCTS
11.1 List of Pollen Allergy Marketed Drugs Across the Top 7 Markets
11.1.1 Grastek (Grass pollen allergy vaccine table) - ALK-Abello
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ragwitek (Ragweed allergy vaccine sublingual tablet) - ALK-Abello
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Oralair (Grass pollen allergy immunotherapy) - Stallergenes Greer plc
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLLEN ALLERGY - PIPELINE DRUGS
12.1 List of Pollen Allergy Pipeline Drugs Across the Top 7 Markets
12.1.1 REGN5713-5714-5715 - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLLEN ALLERGY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLLEN ALLERGY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLLEN ALLERGY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pollen Allergy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pollen Allergy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pollen Allergy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pollen Allergy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pollen Allergy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pollen Allergy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pollen Allergy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pollen Allergy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pollen Allergy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pollen Allergy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pollen Allergy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pollen Allergy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pollen Allergy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pollen Allergy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pollen Allergy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pollen Allergy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pollen Allergy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pollen Allergy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pollen Allergy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pollen Allergy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pollen Allergy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pollen Allergy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pollen Allergy - Access and Reimbursement Overview
16 POLLEN ALLERGY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLLEN ALLERGY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLLEN ALLERGY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
